Lilly Endowment Has Sold $111.8B in LLY Stock — But It's Not a Bearish Signal

The Lilly Endowment Inc has sold $111.8 billion in Eli Lilly stock since 2003—making it one of the largest systematic sell programs in SEC filing history. Yet this is not a bearish signal. It’s foundation law.

The Scale of the Sell Program

The Lilly Endowment, one of America’s largest charitable foundations with assets exceeding $14 billion, has executed 10,747 Form 4 transactions in Eli Lilly stock over 22 years. The endowment still holds 92.2 million shares—a 10%+ beneficial ownership stake—but the sheer volume of sales requires explanation.

Recent activity shows the pattern continues: in late November 2025, the endowment sold shares across 20+ separate Form 4 filings, each at prices between $1,082 and $1,110 per share. In December 2025, sales continued, with the most recent transaction on December 29, 2025, at $1,085.04 per share.

Why Foundations Must Diversify

The Lilly Endowment inherited its massive LLY stake from the Lilly family’s founding ownership. Federal law and foundation governance rules require endowments to:

• Diversify holdings to reduce concentration risk and ensure long-term stability
• Maintain prudent asset allocation across multiple sectors and asset classes
• Distribute 5% annually to charitable causes (required by tax law)
• Avoid over-reliance on a single security that could jeopardize the foundation’s mission

The Lilly Endowment’s systematic selling is not a vote of no-confidence in Eli Lilly. It’s a fiduciary obligation to rebalance a portfolio that would otherwise be dangerously concentrated in a single stock.

The Endowment Remains a Major Shareholder

Despite $111.8 billion in cumulative sales, the Lilly Endowment remains one of Eli Lilly’s largest shareholders. The endowment’s 92.2 million shares represent approximately 6.5% of the company’s outstanding equity—a position that would take decades to fully liquidate at current selling rates.

This is the key distinction: the endowment is not exiting its position. It is slowly, methodically rebalancing a legacy holding to fund its charitable mission while maintaining a significant stake in the company its founder built.

What to Watch

• Endowment distribution rate—If the Lilly Endowment increases its annual charitable distributions, LLY sales may accelerate to fund those commitments
• Eli Lilly stock price—The endowment appears to use price-based triggers for sales; higher prices may trigger larger tranches
• Sector rotation—Monitor the endowment’s 13F filings to see which sectors it is rotating proceeds into (healthcare, technology, fixed income)
• Remaining LLY stake—At current selling rates, the endowment will hold a meaningful LLY position for at least another 20+ years

Key Facts

Metric	Value
Total LLY Sales (Career)	$111.8 billion
Total Transactions	10,747
Current LLY Holdings	92.2 million shares
Beneficial Ownership %	~6.5% of LLY
First Transaction	July 31, 2003
Most Recent Transaction	December 29, 2025
Endowment Total Assets	$14+ billion

For the full transaction history and insider profile, visit the Lilly Endowment profile page.